Dr. Celanire gathered 15 years of experience in drug discovery and development in the pharmaceutical industry. He holds a PhD in medicinal chemistry from the University of Rouen (1999). During two successive postdoctoral fellowship at the University of Orleans and Oxford, he collaborated with Teva (formerly Cephalon/Laboratories Laffon) and Hoffmann-la Roche on natural product syntheses with broad anticancer and antibiotic therapeutic applications respectively. In 2002, he joined UCB CNS Center (Belgium), leading multiple preclinical programs targeting neurodegenerative and neurological disorders, in particular first-in-class Histamine H3R modulators, leading ultimately to clinical candidate UCB2892. In 2007, Dr. Celanire joined the Swiss biotech Addex Therapeutics where he successfully hold the positions of Project Leader, Group Leader of the CNS Medicinal Chemistry Unit and Associate Research Director until 2013. He advanced multiple programs and first-in-class orally active small molecules acting as positive and negative allosteric modulators of metabotropic glutamate receptors therapeutic class (mGlu2, mGlu4) from hits to preclinical candidates. In particular, he developed best-in-class mGlu4 PAMs in collaboration with Merck&Co – US for Parkinson’s disease, with additional therapeutic potential in anxiety, autism and multiple sclerosis. Dr. Celanire was also involved in the in&out licensing project portfolio evaluation with US and European companies.
Dr. Celanire has co-authored more than 26 original research articles, review articles and book chapters as well served as editor for Springer Drug Discovery series. He is co-inventor of more than 20 patents applications.
Guillaume Duvey, PhD
Dr. Duvey has spent 15 years in the pharmaceutical and biotechnology industry, focusing on drug discovery and development for critical diseases in the neuroscience field. After a PhD in medicinal chemistry awarded in 2000 from University of Rouen (France), Dr. Duvey joined the R&D division of Janssen in France to advance several research programs in the various fields of oncology, virology and CNS disorders. In 2004, he joined the Swiss biotechnology start-up Addex therapeutics where he led several preclinical programs, developing in particular novel allosteric modulators for glutamate receptors (mGlu2, mGlu5 and mGlu7) for various indications. These discoveries led to numerous small molecule clinical candidate nominations for therapeutic indications like Parkinson’s disease, anxiety, pain, gastroesophageal reflux disease and mood disorders. Dr. Duvey notably led the research collaboration with Janssen Pharaceuticals in Belgium and Spain (J&J group), to develop novel mGlu2 allosteric modulators for the treatment of schizophrenia and anxious depression. This collaboration successfully allowed the identification of the clinical candidate ADX71149/JNJ40411813 currently in Phase 2 clinical development. In 2010, he held senior scientific management position, and as Group Leader was responsible for the medicinal chemistry of the metabolic disorder and inflammation business units, driving a team of 11 scientists. He is co-author of more than 25 patents and peer-reviewed articles, as well as a book chapter dedicated to drugs acting on mGlu2 and mGlu5.
In addition to his scientific accomplishments, Dr. Duvey served as Research Director from 2012, where he was responsible for developing strategical scientific partnerships and technological platform integrating modern techniques for identification, characterization and optimization of preclinical molecules for novel targets and new indications.
As CSO, Dr. Duvey will oversee the scientific operations of the company and will drive forward PRAGMA’s program, both in house and through partners, into clinical Proof-of-Concept studies.
Director Business Development
Dr. Vincent Mutel, is currently CEO and Board member of InflamAlps and Tauderma biotechs. He was previously CEO, co-founder and vice chairman of the board of Addex Pharmaceuticals Ltd, a well-established public Swiss biotech, pioneer in allosteric modulation of metabotropic glutamate receptors class. Dr Mutel was Research Area Head in the CNS division at the Swiss pharmaceutical company F. Hoffmann-La Roche Ltd where he worked for 13 years. Vincent is a biochemist and pharmacologist by training and has initiated and successfully driven several R&D projects bringing molecules from discovery to advanced clinical trial.
In his role at Addex Pharmaceuticals Ltd he led the growth of the organization to up to 140 staff, completed three rounds of venture financing, an IPO and a PIPE, totaling CHF263 million, and signed three major drug development partnerships, two with Merck & Co., Inc. and one with Ortho-McNeil-Janssen Pharmaceuticals Inc., a Johnson & Johnson company, representing CHF43 million in realized revenues.
Dr Mutel is co-author of more than 80 scientific papers and review articles, and co-inventor of 20+ patent applications, mostly related to glutamate receptors modulators (NMDA and mGlu).